Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 3312345...102030...Last »

QuintilesIMS white paper: Large benefit for small numbers

The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.

Read More »

First Year After Launch: New molecular entities launched in the U.S. during 2015 that generated 2016 sales of at least $200 million

A listing of the the new molecular entities launched in the United States during 2015 that generated 2016 sales of at least $200 million

Read More »

Samsung Bioepis launches Remicade biosmiliar

South Korea’s Samsung Bioepis started U.S sales of its copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.

Read More »

AbbVie Receives CHMP Positive Opinion for Humira

The EMA’s CHMP granted a positive opinion for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age.

Read More »

CSL Behring Receives Orphan-Drug Exclusivity for Haegarda

FDA granted orphan-drug exclusivity for Haegarda for the prevention of hereditary angioedema attacks.

Read More »

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

(Reuters) – European regulators on Friday recommended approving Pfizer Inc and Merck KGaA’s immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma. In May, Bavencio was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma. (bit.ly/2vIbPPG) Bavencio, known […]

Read More »

EU medicines agency recommends approval of Novartis leukemia drug Rydapt

ZURICH (Reuters) – A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfolio. The EMA’s Committee for Medicinal Products for Human Use (CHMP) backed Rydapt against acute myeloid leukemia […]

Read More »

UK will pay for Roche breast cancer drug

A breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely following a discount deal between Roche and the NHS.

Read More »

Hundreds of Patient Deaths Linked to Roche’s RA Drug Actemra

Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.

Read More »

The Best Defense is a Good Quality Offense

While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?

Read More »

New MS Drug Linked to Deadly Brain Infection

Roche is investigating a case of a German patient diagnosed with a deadly brain infection called PML after taking one dose of the company’s new MS drug Ocrevus.

Read More »

WHO wants transparency, market revamp for fairer drug pricing therape

The world needs greater transparency on the pricing of medicines – and an overhaul of some approaches – in order to increase access to life-saving drugs, global health experts said.

Read More »

In Europe, U.S., modern AIDS drugs add extra 10 years of life expectancy

Life expectancy for young HIV-positive adults has risen by 10 years in the United States and Europe.

Read More »

U.S. prescription drug spending as high as $610 billion by 2021: report

Spending on prescription medicines in the United States will increase 4-7 percent through 2021, reaching $580 billion to $610 billion, according to a report released by QuintilesIMS Holdings.

Read More »

GSK’s Advair faces first direct competition

Teva Pharmaceutical Industries Ltd. launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.

Read More »

Trump Taps Congressman as Next ‘Drug Czar’

President Trump, hoping to take on the opioid epidemic sweeping parts of America, tapped U.S. Rep. Tom Marino to head up the Office of National Drug Control Policy.

Read More »

Changing the Learning Curve for Auto-Injection Therapy

As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.

Read More »

GSK’s new CEO gets short-term win from generic Advair delay

GlaxoSmithKline’s new CEO Emma Walmsley won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.

Read More »

U.S. lawmakers seek pricing info on DMD drug

Two U.S. lawmakers sent a letter to PTC Therapeutics Inc. seeking information about the drugmaker’s pricing strategy for its recently acquired muscle-wasting disorder drug.

Read More »

Harvoni Study: 97% of Hep C Patients Cured

Nearly all patients who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni were cured of the disease, according to PBM Prime Therapeutics.

Read More »

Page 2 of 3312345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2017 Focus: Ad Agency Roundtable and more!

Subscribe

Ad Right Bottom

Main Navigation